IP Library Granted Patent US 11,071,812
Granted Patent B2
US 11,071,812 · App. 15/608,023 · Granted Jul 27, 2021

Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood

Inventors: Karthik Raman (Union City, CA); Colin Yee (Fremont, CA); Chia-Hung Sze (St. Louis, MO); Arthur John Lockhart (San Ramon, CA); David Barry (San Ramon, CA)
Assignee: PENUMBRA, INC.
A61M1/3615A61M1/3679B01J39/04B01J39/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,071,812
App. No.
15/608,023
Granted
Jul 27, 2021
Kind
B2
Abstract

Doxorubicin is extracted from blood using anionic material, such as a resin comprising sulfonated polystyrene divinylbenzene beads, and polyethersulfone membrane, or both. After exposing the resin and/or membrane to blood in order to remove doxorubicin therefrom, the doxorubicin maybe extracted from the resin and/or membrane by exposing the material to an extraction solution, sonicating the extraction solution to enhance release of the doxorubicin, and repeating the exposure and sonication in order to remove substantially all of doxorubicin from the resin.

Claims (12)

1. A method for measuring doxorubicin present in a patient's blood, said method comprising:

mixing a sample of the patient's blood with a silver nitrate solution;

adding a volume of methanol to the mixture;

further mixing the blood, silver nitrate, and methanol together for at least 10 seconds;

letting the mixed blood, silver nitrate, and methanol stand for at least 30 minutes to precipitate particles and form a supernatant;

separating the supernatant via chromatography, wherein the separated supernatant contains doxorubicin originally present in the blood sample; and

analyzing the separated supernatant via spectroscopy, wherein the UV absorbance of doxorubicin is measured.

2. The method of claim 1 , including the step of analyzing the separated supernatant via spectroscopy at 254 nm.

3. The method of claim 1 , including the step of analyzing the separated supernatant via spectroscopy at 480 nm.

4. The method of claim 1 , wherein a chromatography buffer comprises acetonitrile and NaH 2 PO 4 .

5. The method of claim 1 , wherein the total mixed volume of the sample of the patient's blood with the silver nitrate solution is below 200 μl.

6. The method of claim 1 , wherein the volume of methanol added to the mixture is less than or equal to 1 ml.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: PENUMBRA, INC.
Reel/Frame 066596/0706 →
SECURITY INTEREST Recorded Apr 24, 2020
From: PENUMBRA, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 052488/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2019
From: RAMAN, KARTHIK; YEE, COLIN; SZE, CHIA-HUNG; LOCKHART, ARTHUR JOHN; BARRY, DAVID
To: PENUMBRA, INC.
Reel/Frame 049331/0697 →
Continuity (2)
Provisional Application 62343680 · May 31, 2016
Related Publication 20170340797A1 · Nov 30, 2017
Cited By (6)
US 12,220,139 US 12,262,903 US 12,343,024 US 12,575,844 US 12,642,542 US 12,642,543